The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A first-in-human phase I/Ib study of ATG-037 monotherapy and combination therapy with pembrolizumab in patients with advanced solid tumors: STAMINA-01.
 
Janine Lombard
Honoraria - AstraZeneca; Eisai; Gilead Sciences; GlaxoSmithKline; Novartis
Consulting or Advisory Role - AstraZeneca
 
Joanne Lundy
No Relationships to Disclose
 
Adnan Khattak
No Relationships to Disclose
 
Andrea Tazbirkova
Research Funding - Antengene; Arcus Biosciences; BeiGene; Checkpoint Therapeutics; Janssen-Cilag; Novotech
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Lilly; MSD; Pierre Fabre; Roche
 
Faisal Hayat
No Relationships to Disclose
 
Qing Zhou
Honoraria - AstraZeneca; Boehringer Ingelheim; Lilly; MSD; Pfizer; Roche
 
Yongsheng Li
No Relationships to Disclose
 
Anupa Kudva
Employment - Antengene
 
Hao Cui
Employment - Antengene
 
Jun Zhao
Employment - Antengene
 
Zhi Guo
Employment - Antengene
 
Michael Chisamore
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Yi-Long Wu
Honoraria - AstraZeneca; BeiGene Beijing; Boehringer Ingelheim; Bristol-Myers Squibb/China; Hengrui Pharmaceutical; MSD Oncology; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Roche; Takeda
Research Funding - BMS (Inst); Boehringer Ingelheim (Inst); Pfizer (Inst); Roche (Inst)